1. Home
  2. RDNT vs BLCO Comparison

RDNT vs BLCO Comparison

Compare RDNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDNT
  • BLCO
  • Stock Information
  • Founded
  • RDNT 1985
  • BLCO 1853
  • Country
  • RDNT United States
  • BLCO Canada
  • Employees
  • RDNT N/A
  • BLCO N/A
  • Industry
  • RDNT Medical Specialities
  • BLCO Ophthalmic Goods
  • Sector
  • RDNT Health Care
  • BLCO Health Care
  • Exchange
  • RDNT Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • RDNT 5.9B
  • BLCO 7.0B
  • IPO Year
  • RDNT 1986
  • BLCO 2022
  • Fundamental
  • Price
  • RDNT $81.57
  • BLCO $19.64
  • Analyst Decision
  • RDNT Strong Buy
  • BLCO Buy
  • Analyst Count
  • RDNT 4
  • BLCO 11
  • Target Price
  • RDNT $74.75
  • BLCO $21.30
  • AVG Volume (30 Days)
  • RDNT 590.7K
  • BLCO 477.2K
  • Earning Date
  • RDNT 11-10-2024
  • BLCO 10-30-2024
  • Dividend Yield
  • RDNT N/A
  • BLCO N/A
  • EPS Growth
  • RDNT N/A
  • BLCO N/A
  • EPS
  • RDNT N/A
  • BLCO N/A
  • Revenue
  • RDNT $1,772,946,000.00
  • BLCO $4,684,000,000.00
  • Revenue This Year
  • RDNT $12.83
  • BLCO $17.44
  • Revenue Next Year
  • RDNT $8.66
  • BLCO $6.18
  • P/E Ratio
  • RDNT N/A
  • BLCO N/A
  • Revenue Growth
  • RDNT 12.20
  • BLCO 18.01
  • 52 Week Low
  • RDNT $32.00
  • BLCO $13.16
  • 52 Week High
  • RDNT $93.65
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • RDNT 66.81
  • BLCO 44.49
  • Support Level
  • RDNT $77.34
  • BLCO $19.31
  • Resistance Level
  • RDNT $93.65
  • BLCO $20.23
  • Average True Range (ATR)
  • RDNT 3.22
  • BLCO 0.48
  • MACD
  • RDNT 0.64
  • BLCO -0.13
  • Stochastic Oscillator
  • RDNT 58.24
  • BLCO 5.48

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: